Core Insights - The pharmaceutical sector reported a slight revenue growth of 0.20% year-on-year for Q3 2025, driven by innovative drugs and CXO benefiting from overseas orders and FDA approvals [1] - The medical device sector is experiencing slow recovery, with capital expenditures in hospitals remaining low, particularly in high-end imaging and IVD fields [1] - Traditional Chinese medicine saw a revenue increase of 1.60% year-on-year, but profits were pressured by adjustments in medical insurance catalogs and centralized procurement [1] - Pharmaceutical commercial revenue grew by 2.45%, although gross margins declined by 0.85 percentage points, indicating intensified price pressures in distribution channels [1] Short-term Outlook - The easing of centralized procurement policies for medical devices and steady progress in the innovative drug industry suggest stable operational performance in the pharmaceutical sector, with innovative drugs experiencing six consecutive quarters of high growth [1] - 2025 is anticipated to be a pivotal year for commercial insurance, benefiting innovative drugs and devices along with their supply chains [1] Long-term Outlook - The continuous upgrade of China's pharmaceutical industry is being realized, supported by a series of domestic policies favoring innovative drugs and the increasing clinical value of products [1] - Global pharmaceutical companies are accelerating their purchases of innovative drugs from China, surpassing the pace seen in the U.S. and other countries, indicating a collective globalization of China's innovative drug industry [1] Focus Areas - Future attention will be directed towards three main areas: 1. Innovative drugs with strong global competitiveness, benefiting from both domestic and Western markets [2] 2. The innovative drug supply chain, including CXO and life sciences services, expected to see a recovery in order growth as global investment and financing accelerate [2] 3. Medical devices and equipment, particularly companies focusing on self-sufficiency, domestic substitution, and high-end manufacturing for international markets, as procurement policies continue to improve [2]

Core Insights - Hangzhou's biopharmaceutical industry is experiencing significant growth, with the approval of the innovative drug "维培那肽注射液" (brand name "派达康") marking the fifth first-class innovative drug approved in the city this year [1] - The city accounts for 75% of the first-class innovative drug applications in the province, leading in several key metrics [1] Group 1: Drug Development and Innovation - The innovative drug "维培那肽" utilizes a PEGylation technology that effectively resists DPP-4 enzyme degradation and significantly reduces renal clearance rates, ensuring high bioactivity and prolonged exposure time in clinical treatments [1] - During the "14th Five-Year Plan" period, 12 innovative drug specifications were approved in Hangzhou, representing 54.5% of the province's total [1] - By the third quarter of 2025, the province had 647 new drug applications, with Hangzhou contributing 262 applications, or 40.5% of the total [1] Group 2: Industry Support and Services - Hangzhou has 133 pharmaceutical manufacturing companies and approximately 103 clinical trial and new drug application institutions, with nearly 300 innovative drug clinical projects approved [2] - The city has implemented a "one-stop" service model to reduce operational and communication costs for enterprises, including personalized guidance and dynamic monitoring of innovative product demands [2] - The local market supervision department has proactively assisted companies by addressing issues and facilitating access to special funds, thereby alleviating financial pressures [2]

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a correction, with the Hang Seng Pharmaceutical ETF (159892) dropping over 1%, while innovative drug companies are seeing increased capital inflow after a period of adjustment [1] Group 1: Market Performance - The Hang Seng Pharmaceutical ETF has seen continuous capital subscriptions for four consecutive days despite the recent decline in innovative drug stocks [1] - Notable declines were observed in companies such as Yimeng Biotech, MicroPort Medical, Keren Biotechnology, and Zai Lab [1] Group 2: Industry Support and Trends - Industrial chain fundamentals for innovative drugs are showing signs of improvement, with positive trends in financing data, orders, and performance [1] - The Chongqing municipal government has announced comprehensive measures to support the high-quality development of innovative drugs, including funding for research and rapid integration of innovative drug application lists [1] Group 3: ETF Focus - The Hang Seng Pharmaceutical ETF tracks the Hang Seng Biotechnology Index, focusing on the innovative drug industry while also covering segments like CXO and online pharmacies, aligning with the main investment themes of innovation and international expansion in the pharmaceutical sector [1]

Core Viewpoint - The recent shift in market sentiment towards Hong Kong stocks is driven by two main themes: external macro liquidity turning points and internal industry fundamentals improving, particularly in the innovative pharmaceutical sector [2][4]. Group 1: External Catalysts - The macro liquidity environment is expected to change positively due to the end of the U.S. government shutdown, which will release previously locked liquidity from the TGA account, signaling a shift towards looser liquidity conditions [5][7]. - The anticipated resumption of non-farm employment data is likely to catalyze expectations for interest rate cuts, further improving the dollar liquidity environment [6][7]. - Hong Kong stocks are particularly sensitive to changes in dollar liquidity, making them a leading indicator for capital flows in response to the expected fiscal normalization and interest rate cuts [7][8]. Group 2: Internal Drivers - The innovative pharmaceutical sector in Hong Kong has shown resilience, with a reported revenue growth of 23.34% year-on-year in the first three quarters of 2025, despite pressures from centralized procurement and healthcare cost controls [9]. - Upcoming results from the Medicare negotiations and the first commercial insurance innovative drug price negotiations are expected to provide new growth opportunities for innovative drug companies [9][10]. - The diversification of the payment system, combining Medicare and commercial insurance, is anticipated to alleviate payment pressures and expand market potential for high-value innovative drugs [10]. - The Chinese biotech sector is entering a "2.0 era" of innovation output, with a significant pipeline of new drugs and indications expected to drive future performance [10]. Group 3: Dual Resonance - The convergence of external liquidity improvements and strong internal fundamentals positions the Hong Kong innovative pharmaceutical sector as a focal point for recovery [11]. - The sector's high sensitivity to financing conditions means that any easing of liquidity will likely lead to rapid valuation recovery [11][12]. - The solid performance metrics and upcoming catalysts provide a robust foundation for sustained growth in the sector, making it an attractive investment opportunity [12][13].

Group 1: Computer Industry Investment Strategy - The year 2025 marks the beginning of domestic computing power industrialization, with significant advancements in domestic AI chips and server architecture, enhancing overall computing performance [10] - The gap between Chinese and American large models is narrowing, with expectations of further convergence and potential surpassing in certain areas by 2026 [10] - The software industry is entering an optimal layout window as AI revenue for many companies exceeds 10%, indicating a technological revolution [10] - Investment focus areas include Deep Research, AI programming, multi-modal applications, and industry-specific agents [10] Group 2: Real Estate Industry Investment Strategy - The real estate market is expected to structurally bottom out, with five major opportunities identified, including stabilization of residents' balance sheets and improved housing affordability [12][18] - The policy direction will focus on stabilizing demand and promoting high-quality development, which will benefit real estate companies [18] - Predictions for 2025-2026 include a decline in sales volume and prices, but core cities are expected to stabilize sooner due to healthier supply-demand relationships [18] Group 3: Pharmaceutical Industry Investment Strategy - Chinese pharmaceutical companies are increasingly leading global multi-center clinical trials, with a growing number of new drugs successfully commercialized overseas [15] - The shift from "fast following" to "innovation leading" in drug development positions Chinese companies to redefine the global pharmaceutical landscape [15] - Investment directions include biotech transitioning to biopharma and the revaluation of traditional pharmaceutical companies during their innovation transformation [15]

对于为何终止定增，盟科药业表示，公司主要股东Genie Pharma持续反对公司按照股东大会决议推进发行方案的 执行，与公司其他股东、公司管理层之间存在较大分歧。 长江商报记者发现，Genie Pharma为盟科药业第一大股东，持股7157.28万股，占比达10.92%。 长江商报消息视觉中国图 ●长江商报记者 黄聪 筹划约两个月，盟科药业（688373.SH）定增无奈告吹。 11月17日晚间，盟科药业发布公告称，公司审议通过了《关于终止向特定对象发行股票事项的议案》。此前，公 司公告显示，拟发行1.64亿股股份募集资金10.33亿元，全部用于公司日常研发与经营投入。 业绩方面，盟科药业首款产品自2021年正式销售，此后公司收入开始大幅增长。不过，公司目前尚未摆脱亏损局 面，2018年至2024年以及2025年前三季度，公司近8年时间里归母净利润累计亏损超过18.5亿元。 在研发上，盟科药业近8年研发费用合计超过14.8亿元。其中，公司2025年前三季度研发费用率达166%。 然而，目前，盟科药业并无生产能力，全部产品委托华海药业代工。同时，公司生产工艺研发、药学研发及 CDMO业务亦主要通过委外方式实施。 ...

Core Viewpoint - The core logic for global asset allocation in 2026 is to "follow the direction of credit expansion" [1] Group 1: Market Dynamics - The hidden mainline of the market is that the direction of credit expansion determines the strength of assets and the flow of funds [3] - The past couple of years in the Chinese market have been characterized by "excess liquidity" chasing "scarce return assets," with the recognized scarce assets changing over time [3] - Key factors for future market judgment include whether the liquidity environment has been damaged and whether scarce assets can expand to a broader range [3] Group 2: Credit Expansion and Investment Strategy - The investment strategy for 2026 is framed around the "credit cycle," focusing on three main subjects of credit expansion [4] - In the Chinese market, the credit cycle is expected to experience a slowdown, with structural prosperity still present despite challenges [6] - The U.S. market is seeing a gradual recovery in the credit cycle, supported by fiscal and monetary easing, with no significant signs of bubble formation in AI investments [7] Group 3: Structural Opportunities in China - The overall credit cycle in China is expected to face challenges starting from Q4, but structural prosperity remains effective [9] - The correlation between market performance and economic expectations has increased, indicating a need to focus on structural trends for excess returns [9] - Three structural directions for prosperity include AI-driven trends, capacity cycle reversals, and external demand mapping [9] Group 4: Hong Kong Market Outlook - The outlook for the Hong Kong market in 2026 suggests limited index space, with potential growth coming from structural changes or unexpected pullbacks rather than pure valuation expansion [11] - The Hang Seng Index's dynamic valuation is currently at 11.4 times, indicating a position above the historical average, suggesting that the market is not "cheap" [11] Group 5: Recommended Investment Directions - It is advisable to maintain a moderate allocation to dividend assets to counter the weakening of the overall credit cycle [13] - Key sectors to focus on include AI software and hardware, electric new energy, chemicals, home furnishings, and innovative pharmaceuticals, with careful consideration of valuation and crowding [13] - A potential rise in China's PPI towards the end of this year could provide an opportunity for market shifts towards cyclical and certain consumer sectors [14]

Core Insights - Recent actions by the Federal Reserve have made "liquidity crisis" a hot topic in the market, with bank reserves dropping to $2.83 trillion and the Libor-OIS spread reaching 110 basis points, indicating clear signs of tightening liquidity [1][2] - Global central banks are simultaneously shifting towards easing, creating a "firewall" for the market, suggesting that investors should focus on preemptive strategies rather than worrying about the potential for a crisis [1][2] Indicators for Identifying Liquidity Crisis - **Interest Rate Signals**: A sharp increase in financing costs, such as the overnight financing rate exceeding the Fed's target range and the widening Libor-OIS spread, serves as early warning signs of liquidity depletion [1][2] - **Asset Signals**: A simultaneous decline in stocks, bonds, and gold is a dangerous signal, indicating a liquidity crisis where all assets are sold for cash. Recent market behavior shows that U.S. stocks and gold have not experienced synchronized declines, suggesting liquidity has not yet dried up [1][2] - **Policy Signals**: The activation of emergency measures by central banks, such as the Fed's standing repo facility and the ECB's expansion of asset purchases, indicates that liquidity stress has reached a critical level. Current Fed actions, including halting balance sheet reduction and a 25 basis point rate cut, are seen as preventive measures rather than emergency interventions, implying a low probability of crisis [2] Strategies for Crisis Management - **De-leveraging**: Investors should promptly divest from high-debt assets, as leverage amplifies risks during a liquidity crisis. Strategies include reducing the use of margin financing and prioritizing the sale of high-debt sector assets [3] - **Avoiding Crowded Trades**: Investors should steer clear of popular assets that are prone to concentrated selling during a crisis, as seen in past market downturns. Current overhyped sectors, such as AI stocks, may appear liquid but can collapse quickly in panic [3] - **Maintaining Cash and Short-Duration Bonds**: A balanced approach involving cash and short-term bonds is essential. Investors should avoid mismatched durations and ensure they can access liquidity when needed [4] Asset Allocation Recommendations - **Liquidity Assets (50%)**: This portion should consist of money market funds, demand deposits, and short-term government bonds to cover immediate cash needs [5] - **Core Assets (30%)**: Investments in undervalued, high-dividend blue-chip stocks and quality bond funds should be prioritized for stability and long-term growth [5] - **Growth Assets (20%)**: Allocating to growth stocks, sector ETFs, and gold can provide higher returns during liquidity easing, while still maintaining overall portfolio safety [5] Conclusion - A liquidity crisis is not an end but a test of resilience. Current data suggests a low probability of a widespread liquidity crisis, but investors should remain prepared with a solid plan. Historical evidence shows that those who proactively manage leverage, maintain cash reserves, and select quality assets can navigate through crises effectively [6]

Investment Rating - The industry investment rating is "Recommended (Maintain)" [1] Core Views - The innovative drug industry chain continues to show strong performance, with the pharmaceutical and biotechnology sector outperforming the CSI 300 index, rising by 3.29% while the index fell by 1.08% during the week of November 10 to November 14, 2025 [9][10] - The market potential for small nucleic acids is continuously increasing, indicating that it may become a significant technological hotspot in innovative drugs [19][22] - The sentiment in the innovative drug sector has recently declined, but the sustainability of the sector's prosperity is expected to continue, with a focus on "innovation + internationalization" [22][24] Summary by Sections 1. Weekly Pharmaceutical Sector Performance - The pharmaceutical and biotechnology sector has shown a year-to-date increase of 22.99%, outperforming the CSI 300 index by 5.38 percentage points [9] - The sector's valuation as of November 14, 2025, is 30.89 (PE, TTM), with a premium of 129.74% over the CSI 300 index [10] 2. Industry Events/Policy Overview - On November 14, 2025, the National Bureau of Statistics reported a stable economic performance, with industrial production increasing by 4.9% year-on-year [17] - The People's Bank of China reported an increase of 14.97 trillion yuan in RMB loans in the first ten months of 2025 [17] 3. Industry Investment Strategy - The report highlights the active business development (BD) transactions in the innovative drug sector, with significant collaborations and licensing agreements, such as the partnership between Sainty Biotech and Eli Lilly [19] - The report suggests a focus on the recovery of the medical device and traditional Chinese medicine sectors, as well as the ongoing improvement in the innovative drug industry chain [22][28] 4. Recommended Stocks - Recommended stocks include: - **Hengrui Medicine**: Expected to achieve rapid growth in both domestic and international markets [29] - **BeiGene**: Anticipated to achieve comprehensive profitability in 2025, with strong performance in its core products [30] - **Innovent Biologics**: Expected to reach a revenue target of 20 billion yuan by 2027 [31] - **Kanglong Chemical**: Projected to see significant revenue growth driven by its innovative products [32] - **WuXi AppTec**: Anticipated to maintain rapid growth in its core business and increase global production capacity [33]

Core Viewpoint - After being removed from the Hong Kong Stock Connect list in March, the stock price of Kedi-B (02487) experienced significant volatility, initially dropping to a low of HKD 3.64 but later rebounding by 250% due to strong financial results and market conditions [1][4][10]. Financial Performance - Kedi reported a total revenue increase of approximately 103% year-on-year for the fiscal year 2024, with gross profit rising by about 102% [4]. - The net loss for the period narrowed by 77.91% compared to the previous year, attributed to increased sales of hair loss and skincare products, as well as cost-cutting measures [4][12]. - The company’s half-year report for 2023 showed a revenue decrease of 30.6% to approximately HKD 66.3 million, with a net loss of about HKD 239 million, reflecting challenges due to strategic changes in partnerships [11][12]. Stock Price Movement - Following the announcement of its annual report on April 22, Kedi's stock price rebounded significantly, reaching a peak of HKD 7.62 on May 20, recovering all losses incurred after being removed from the Stock Connect [4][5]. - The stock price saw a decline from a high of HKD 12 to a low of HKD 5.87, marking a maximum drop of 51.08% over two months [8][10]. Market Dynamics - The stock's performance was influenced by the overall recovery of the Hong Kong pharmaceutical sector and the company's solid financial fundamentals [4][11]. - The liquidity issues stemming from the removal from the Stock Connect were exacerbated by the stock's volatility, with a significant reduction in the proportion of holdings by Stock Connect investors from 10.09% to 4.10% between March and June [5][7]. Future Prospects - Kedi plans to issue 28.9 million shares at a price of HKD 8.40 each to raise approximately HKD 240 million, with 45% of the proceeds allocated for the marketing and development of new products CU-40102 and CU-10201 [12]. - Market forecasts suggest that CU-40102 could achieve first-year revenues exceeding HKD 100 million, with peak sales potential estimated between HKD 1 billion and HKD 2 billion, while CU-10201 is projected to generate around HKD 50 million in its first year [12].